ABCL is trading at $8.20 (4.2% up) in pre-market following the appointment of Dr. Lynn Seely, an oncology veteran, to its Board of Directors. - Dr. Seely brings extensive experience in oncology and commercializing complex therapies, which is expected to influence AbCellera's pipeline and commercialization strategies. - This new company-specific development provides a catalyst for today's price movement.